- Home
- ZNTL vs ACB Comparison
ZNTL vs ACB Comparison
Compare ZNTL & ACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- ACB
- Stock Information
- Founded
- ZNTL 2014
- ACB 2013
- Country
- ZNTL United States
- ACB Canada
- Employees
- ZNTL N/A
- ACB N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- ACB Pharmaceuticals and Biotechnology
- Sector
- ZNTL Health Care
- ACB Health Care
- Exchange
- ZNTL Nasdaq
- ACB Nasdaq
- Market Cap
- ZNTL 238.2M
- ACB 315.4M
- IPO Year
- ZNTL 2020
- ACB N/A
- Fundamental
- Price
- ZNTL $3.12
- ACB $6.09
- Analyst Decision
- ZNTL Buy
- ACB Hold
- Analyst Count
- ZNTL 7
- ACB 1
- Target Price
- ZNTL $10.86
- ACB N/A
- AVG Volume (30 Days)
- ZNTL 1.2M
- ACB 725.9K
- Earning Date
- ZNTL 11-04-2024
- ACB 11-07-2024
- Dividend Yield
- ZNTL N/A
- ACB N/A
- EPS Growth
- ZNTL N/A
- ACB N/A
- EPS
- ZNTL N/A
- ACB N/A
- Revenue
- ZNTL $40,560,000.00
- ACB $203,838,819.00
- Revenue This Year
- ZNTL N/A
- ACB $14.04
- Revenue Next Year
- ZNTL N/A
- ACB $8.94
- P/E Ratio
- ZNTL N/A
- ACB N/A
- Revenue Growth
- ZNTL N/A
- ACB 12.30
- 52 Week Low
- ZNTL $2.83
- ACB $2.84
- 52 Week High
- ZNTL $18.24
- ACB $9.35
- Technical
- Relative Strength Index (RSI)
- ZNTL 44.34
- ACB 62.13
- Support Level
- ZNTL $2.92
- ACB $5.45
- Resistance Level
- ZNTL $3.23
- ACB $5.66
- Average True Range (ATR)
- ZNTL 0.17
- ACB 0.21
- MACD
- ZNTL 0.00
- ACB 0.06
- Stochastic Oscillator
- ZNTL 38.33
- ACB 87.21
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
About ACB Aurora Cannabis Inc.
Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements.